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A Case of Therapy-Related Acute 
Myeloid Leukemia Following 
5-Fluorouracil Chemotherapy
To the Editor,
Therapy-related acute myeloid leukemia (t-AML) typi-
cally occurs after exposure to alkylating agents, topoi-
somerase II inhibitors, other chemotherapeutics such as 
bimolane, or radiotherapy. Often, these secondary cancers 
have specific clinical and cytogenetic features [1]. The risk 
of t-AML development secondary to the use of antime-
tabolites alone is lower than that associated with the use of 
alkylating agents, although this risk remains higher than 
that in the general population. Although 5-fluorouracil (5-
FU) is relatively frequently used in oncology, to our knowl-
edge t-AML related to 5-FU has rarely been reported [2]. 
We present the case of a patient diagnosed with AML who 
previously received folinic acid (FA) and 5-FU as an adju-
vant treatment for colon cancer following surgery.
A 60-year-old man presented with general weakness 
and extreme fatigue. Forty months earlier, he had been 
diagnosed with stage IIB sigmoid colon cancer accord-
ing to the American Joint Committee on Cancer (AJCC) 
staging system (T4N0M0). The mass was attached to the 
left diaphragm, and he received treatment with an ex-
tended left colectomy and subsequent radiation therapy 
(4,500 rad) of the left diaphragm in the 5 weeks following 
surgery. Following this, he received six cycles of adjuvant 
chemotherapy with FA and 5-FU (FA 20 mg/m
2, 5-FU 
425 mg/m
2; D1-5 q4 weeks). Following this treatment, 
he remained disease free for 39 months while continuing 
on a daily regimen of doxifluridine (100 mg). On admis-
sion, the patient reported general weakness and dyspnea 
on exertion. He had no fever and no cervical, axillary, or 
inguinal lymphadenopathy. No hepatosplenomegaly or 
abnormal skin pigmentation was observed. Laboratory 
tests revealed a white cell count of 4.9 × 10
9/L, anemia (7.9 
g/dL hemoglobin), and thrombocytopenia (platelet count 
39 × 10
9/L). The differential showed 54% lymphocytes. 
Liver and kidney function tests were normal. The serum 
tumor marker, carcinoembryonic antigen (CEA), level was 
normal. No evidence of colon cancer recurrence was found 
by gastroscopy, colonoscopy, or whole-body positron emis-
sion tomography-computed tomography (PET-CT). The 
patient was referred to our department for the evaluation 
of pancytopenia. We performed a bone marrow biopsy and 
aspiration. The bone marrow examination showed many 
immature cells (20%) with a high nucleus/cytoplasm (N/C) 
ratio, sky-blue cytoplasm, and prominent nucleoli (Fig. 1). 
The myeloid series were normal in proportion but revealed 
a left shift. The erythroid series were normal in propor-
tion, with increased monocytes. Cytogenetic analysis of 
the bone marrow disclosed 46,XY,t(3;21)(q26;q22) (Fig. 
2). The patient was diagnosed with acute myelogenous 
leukemia. He was treated with induction chemotherapy 
consisting of idarubicin (12 mg/m
2 D1-3) and ara-C (100 
mg/m
2 D1-7). He achieved complete remission following 
the induction chemotherapy. He continues to receive post-
remission chemotherapy with high-dose ara-C.
The term ‘therapy-related leukemia’ is descriptive and 
founded on a patient’s history of exposure to cytotoxic 
agents. Though a causal relationship is suggested, the 
mechanism remains unproven. These neoplasms are 
thought to be the direct outcome of mutational events in-
duced by cytotoxic therapy or via the selection of a myeloid 
clone with a mutator phenotype that has a remarkably 
elevated risk for a mutational event. Several distinct clini-
cal and cytogenetic subtypes of t-AML are recognized; 
these are closely associated with the nature of the preced-
ing treatment. The latency between primary diagnosis 
and therapy-related disease ranges from several months 
to a few years, depending in part on the cumulative dose 
or dose intensity of the precedent cytotoxic therapy, as 
well as on exposure to specific agents. Most patients have 
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clonal chromosome abnormalities in their bone marrow 
cells at diagnosis [3]. Generally, 10-20% of all newly diag-
nosed cases of AML and myelodysplastic syndrome (MDS) 
are secondary to therapeutic regimens. A comparison of 
typical t-AML and our case is shown in Table 1. Clonal 
chromosomal abnormalities, often of a complex nature, 
are identified in most cases of classic therapy-related leu-
kemia. Cytogenetic abnormalities, such as -5/del(5q), -7/
del(7q), t(11q23), complex karyotypes, or +8 have been as-
sociated with t-AML. The most common single abnormal-
ity is monosomy 7(-7), followed in order of frequency by 
del(5q) and -5. Although these same abnormalities are ob-
served in primary MDS and AML de novo, their frequency 
is clearly higher in therapy-related leukemia. Recent 
molecular examination has concentrated on identifying 
a presumptive leukemia suppressor gene in chromosome 
band 5q31, a critical region that is consistently deleted in 
leukemia cells with 5q abnormalities [4]. Secondary chro-
mosomal changes, rather than primary abnormalities, 
leading to large-scale genomic imbalances are features of 
some forms of t-AML.
In our case, cytogenetic analysis showed t(3;21)
(q26;q22). The t(3;21)(q26;q22) translocation is associated 
with myeloid leukemia and results in a chimeric oncop-
rotein containing AML1/RUNX1 alterably fused to EAP, 
MDS1, and/or EVL1. Activation of the AML1-/MDS1-/
EVL1 fusion transcript through t(3;21) defines a very ag-
gressive, therapy-related leukemic blast syndrome. Prior 
treatment with hydroxyurea or other antimetabolites is 
involved as a contributory cause. In a study performed by 
Yin et al. [5], the presence of t(3;21) heralded myeloid blast 
transformation in 14 patients with chronic myelogenous 
leukemia. Most patients had been treated with hydroxy-
Figure 1. (A) Bone marrow biopsy revealed an increased proportion of immature myeloid cells (20%) with a high nucleus/cytoplasm 
ratio, basophilic cytoplasm, and conspicuous nucleoli. The myeloid series were normal in proportion but revealed a left shift. The 
erythroid series were normal in proportion, with increased monocytes (H&E, × 400). (B) Immature cells were diffusely positive for 
myeloperoxidase (MPO, × 400).
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Figure 2. Cytogenetic analysis of the bone marrow disclosed 
46,XY,t(3;21)(q26;q22).park HJ, et al. Therapy-related AML following 5-FU   117
http://dx.doi.org/10.3904/kjim.2012.27.1.115 http://www.kjim.or.kr
urea in advance. Eight of 10 cases of t(3;21)-associated 
AML were secondary tumors following chemotherapy, 
including fludarabine and 5-FU in three patients each and 
etoposide in two patients.
Although the development of a second primary cancer 
cannot be ruled out, the presence of t(3:21)(q26:q22) and 
the prior use of 5-FU suggests t-AML due to 5-FU. Further 
study is needed to improve the therapeutic strategy for, 
and proper diagnosis of, t-AML.
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Table 1. A comparison of typical therapy-related acute myeloid leukemia (t-AML) and our case
Typical t-AML our case
Cytotoxic agents Alkylating agents
Topoisomerase II inhibitors
5-fluorouracil
Time to development of t-AML Alkylating agents: 5-7 yr
Topoisomerase II inhibitors: 2-3 yr
40 mon
Chromosomal abnormalities Loss of chromosomes 5 and/or 7, 
  translocation involving 11q23 or 21q22
t(3;21)(q26;q22)
Treatment  Standard induction → high-dose cytarabine or 
  allogeneic stem cell transplantation
Low-dose cytarabine
Investigational therapy
supportive care
Idarubicin + cytarabine 
 → high-dose cytarabine
prognosis  poor prognosis
Lower complete remission rate and shorter survival 
  than de novo AML
Complete remission state